FNY Managed Accounts’s Teva Pharmaceuticals TEVA Stock Holding History

FNY Managed Accounts’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$9K	Buy	+585	New	+$11.4K	0.01%	160
2017 Q2	–	Sell	-3,834	Closed	-$123K	–	571
2017 Q1	$123K	Buy	+3,834	New	+$131K	0.38%	55
2015 Q3	–	Sell	-5,800	Closed	-$343K	–	563
2015 Q2	$343K	Buy	+5,800	New	+$358K	0.4%	53
2014 Q2	–	Sell	-2,000	Closed	-$106K	–	145
2014 Q1	$106K	Buy	+2,000	New	+$92.4K	0.28%	52

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FNY Managed Accounts's TEVA Position: Q1 2018 in Review

FNY Managed Accounts opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2018: 585 shares worth $9K. The stake represents 0.01% of the portfolio and ranks #160 among its holdings. This is a return to the name: FNY Managed Accounts previously reported a position in TEVA as recently as Q1 2017.

FNY Managed Accounts first reported a position in TEVA in Q1 2014 and has held it in 4 quarters since. The position peaked at $343K in Q2 2015. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

FNY Managed Accounts held 585 shares of Teva Pharmaceuticals worth $9K as of Q1 2018.
Teva Pharmaceuticals was a new FNY Managed Accounts position in Q1 2018.
Teva Pharmaceuticals made up 0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #160 holding.
FNY Managed Accounts first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 4 quarters since.
FNY Managed Accounts's Teva Pharmaceuticals position peaked at $343K in Q2 2015.
506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.